PMID- 29362402
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 2157-9024 (Print)
IS  - 2157-9024 (Electronic)
IS  - 2157-9024 (Linking)
VI  - 7
IP  - 1
DP  - 2018 Jan 24
TI  - The hypoxic tumour microenvironment.
PG  - 10
LID - 10.1038/s41389-017-0011-9 [doi]
LID - 10
AB  - Cancer progression often benefits from the selective conditions present in the 
      tumour microenvironment, such as the presence of cancer-associated fibroblasts 
      (CAFs), deregulated ECM deposition, expanded vascularisation and repression of 
      the immune response. Generation of a hypoxic environment and activation of its 
      main effector, hypoxia-inducible factor-1 (HIF-1), are common features of 
      advanced cancers. In addition to the impact on tumour cell biology, the influence 
      that hypoxia exerts on the surrounding cells represents a critical step in the 
      tumorigenic process. Hypoxia indeed enables a number of events in the tumour 
      microenvironment that lead to the expansion of aggressive clones from 
      heterogeneous tumour cells and promote a lethal phenotype. In this article, we 
      review the most relevant findings describing the influence of hypoxia and the 
      contribution of HIF activation on the major components of the tumour 
      microenvironment, and we summarise their role in cancer development and 
      progression.
FAU - Petrova, Varvara
AU  - Petrova V
AD  - Medical Research Council, Toxicology Unit, Leicester University, Hodgkin 
      Building, Lancaster Road, P.O. Box 138, Leicester, LE1 9HN, UK.
FAU - Annicchiarico-Petruzzelli, Margherita
AU  - Annicchiarico-Petruzzelli M
AD  - Biochemistry Laboratory, IDI-IRCCS, Rome, Italy.
FAU - Melino, Gerry
AU  - Melino G
AD  - Medical Research Council, Toxicology Unit, Leicester University, Hodgkin 
      Building, Lancaster Road, P.O. Box 138, Leicester, LE1 9HN, UK.
AD  - Department of Experimental Medicine and Surgery, University of Rome "Tor 
      Vergata", 00133, Rome, Italy.
FAU - Amelio, Ivano
AU  - Amelio I
AUID- ORCID: 0000-0002-9126-5391
AD  - Medical Research Council, Toxicology Unit, Leicester University, Hodgkin 
      Building, Lancaster Road, P.O. Box 138, Leicester, LE1 9HN, UK. ia119@le.ac.uk.
LA  - eng
GR  - MC_U132670600/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20180124
PL  - United States
TA  - Oncogenesis
JT  - Oncogenesis
JID - 101580004
PMC - PMC5833859
COIS- The authors declare that they have no competing interests.
EDAT- 2018/01/25 06:00
MHDA- 2018/01/25 06:01
PMCR- 2018/01/24
CRDT- 2018/01/25 06:00
PHST- 2017/07/31 00:00 [received]
PHST- 2017/10/04 00:00 [accepted]
PHST- 2018/01/25 06:00 [entrez]
PHST- 2018/01/25 06:00 [pubmed]
PHST- 2018/01/25 06:01 [medline]
PHST- 2018/01/24 00:00 [pmc-release]
AID - 10.1038/s41389-017-0011-9 [pii]
AID - 11 [pii]
AID - 10.1038/s41389-017-0011-9 [doi]
PST - epublish
SO  - Oncogenesis. 2018 Jan 24;7(1):10. doi: 10.1038/s41389-017-0011-9.